The Postherpetic Neuralgia drugs in development market research report provides comprehensive information on the therapeutics under development for Postherpetic Neuralgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Postherpetic Neuralgia. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Postherpetic Neuralgia and features dormant and discontinued products.

GlobalData tracks 20 drugs in development for Postherpetic Neuralgia by 19 companies/universities/institutes. The top development phase for Postherpetic Neuralgia is preclinical with nine drugs in that stage. The Postherpetic Neuralgia pipeline has 20 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Postherpetic Neuralgia pipeline products market are: Medifron DBT, MEDRx and Allodynic Therapeutics.

The key targets in the Postherpetic Neuralgia pipeline products market include Mu Type Opioid Receptor (MOR1 or Mu Opiate Receptor or Mu Opioid Receptor or OPRM1), Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1), and Kappa Type Opioid Receptor (KOR1 or OPRK or OPRK1).

The key mechanisms of action in the Postherpetic Neuralgia pipeline product include Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1) Agonist with two drugs in Preclinical. The Postherpetic Neuralgia pipeline products include five routes of administration with the top ROA being Topical and one key molecule types in the Postherpetic Neuralgia pipeline products market including Small Molecule.

Postherpetic Neuralgia overview

Postherpetic neuralgia (PHN) emerges as the predominant long-term consequence of varicella-zoster virus (VZV) reactivation, commonly known as herpes zoster or shingles. VZV, responsible for childhood varicella (chickenpox), historically affected the majority of American adults before widespread vaccination. While future generations may experience lower rates of herpes zoster and PHN, the latter remains clinically significant. PHN diagnosis heavily relies on history and physical examination, complemented by laboratory tests and targeted imaging for atypical presentations. Prevention involves identifying high-risk populations for VZV contraction and administering vaccines. Early recognition and treatment of acute HZ infection, along with symptom management using multimodal approaches, constitute essential strategies. Despite evolving evidence, prevention is crucial, given PHN’s often refractory nature, with many sufferers achieving only temporary relief despite comprehensive therapy.

For a complete picture of Postherpetic Neuralgia’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.